News Coverage 08.05.19 By: John Carroll Share on Twitter Share on Facebook Share on LinkedIn Close to a decade after Eli Lilly killed it, Jeffrey Bluestone’s ‘breakthrough’ drug is back and being steered to the FDA Related Announcement, Press Release Parker Institute Commits Additional $125M for Audacious Mission to Cure Cancer Announcement, Press Release The Parker Institute for Cancer Immunotherapy Awards More Than $1 Million to Four Early Career Investigators Announcement Behind the Breakthrough: An Interview with Carl June, the Father of CAR T-Cell Therapy
Announcement, Press Release Parker Institute Commits Additional $125M for Audacious Mission to Cure Cancer
Announcement, Press Release The Parker Institute for Cancer Immunotherapy Awards More Than $1 Million to Four Early Career Investigators